Aveo kidney cancer drug some-more tolerated than Nexavar

<p>(Reuters) – Patients holding a <span>kidney cancer</span> drug being grown by <span>Aveo Pharmaceuticals Inc</span> were half as approaching to need a mangle from a remedy due to <span>side effects</span> than those on a widely used medicine Nexavar, according to information expelled on Wednesday.</p>
<p> There were also significantly fewer patients holding Aveo’s tivozanib who compulsory a sip rebate than those on Nexavar.</p>
<p> Aveo, that is building tivozanib along with Japan’s <span>Astellas Pharma</span>, had already expelled rough information from a pivotal investigate display that a drug behind worsening of a illness longer than Nexavar, sole by Bayer AG and <span>Onyx Pharmaceuticals</span>.</p>
<p> The latest data, to be presented during successive month’s <span>American Society of Clinical Oncology</span> (ASCO) assembly...